Cargando…

First-Line Osimertinib in Patients with EGFR-Mutant Advanced Non-Small Cell Lung Cancer: Outcome and Safety in the Real World: FLOWER Study

BACKGROUND: Osimertinib became the standard treatment for patients with untreated EGFR-mutant advanced non-small cell lung cancer (aNSCLC) following results reported in the phase III randomized FLAURA trial. Because of strict exclusion criteria, patient populations included in pivotal trials are onl...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lorenzi, Martina, Ferro, Alessandra, Cecere, Fabiana, Scattolin, Daniela, Del Conte, Alessandro, Follador, Alessandro, Pilotto, Sara, Polo, Valentina, Santarpia, Mariacarmela, Chiari, Rita, Pavan, Alberto, Dal Maso, Alessandro, Da Ros, Valentina, Targato, Giada, Vari, Sabrina, Indraccolo, Stefano, Calabrese, Fiorella, Frega, Stefano, Bonanno, Laura, Conte, Pier Franco, Guarneri, Valentina, Pasello, Giulia
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2021
Materias:	Clinical Trial Results
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9714585/ https://www.ncbi.nlm.nih.gov/pubmed/35641222 http://dx.doi.org/10.1002/onco.13951

Ejemplares similares

Liquid biopsy and non-small cell lung cancer: are we looking at the tip of the iceberg?
por: Bonanno, Laura, et al.
Publicado: (2022)

Clinical features and treatment outcome of non-small cell lung cancer (NSCLC) patients with uncommon or complex epidermal growth factor receptor (EGFR) mutations
por: Frega, Stefano, et al.
Publicado: (2017)

Lung Cancer (LC) in HIV Positive Patients: Pathogenic Features and Implications for Treatment
por: Frega, Stefano, et al.
Publicado: (2020)

Squamous cell carcinomas of the lung and of the head and neck: new insights on molecular characterization
por: Polo, Valentina, et al.
Publicado: (2016)

Novel Nuclear Medicine Imaging Applications in Immuno-Oncology
por: Frega, Stefano, et al.
Publicado: (2020)

Role of next generation sequencing-based liquid biopsy in advanced non-small cell lung cancer patients treated with immune checkpoint inhibitors: impact of STK11, KRAS and TP53 mutations and co-mutations on outcome
por: Pavan, Alberto, et al.
Publicado: (2021)

EGFR T790M testing through repeated liquid biopsy over time: a real-world multicentric retrospective experience
por: Dal Maso, Alessandro, et al.
Publicado: (2022)

Combined Immunoscore for Prognostic Stratification of Early Stage Non-Small-Cell Lung Cancer
por: Boscolo, Alice, et al.
Publicado: (2020)

Non-Small Cell Lung Cancer in a Very Young Woman: A Case Report and Critical Review of the Literature
por: Polo, Valentina, et al.
Publicado: (2015)

Diagnostic-Therapeutic Pathway and Outcomes of Early Stage NSCLC: a Focus on EGFR Testing in the Real-World
por: Pasello, Giulia, et al.
Publicado: (2022)

The Multidisciplinary Approach in Stage III Non-Small Cell Lung Cancer over Ten Years: From Radiation Therapy Optimisation to Innovative Systemic Treatments
por: Ferro, Alessandra, et al.
Publicado: (2022)

Tumor Immune-Infiltrate Landscape After Chemo-Radiotherapy in a Case Series of Patients with Non-small Cell Lung Cancer: Pretreatment Predictors and Correlation With Outcome
por: Pavan, Alberto, et al.
Publicado: (2022)

A Multi-Center, Real-Life Experience on Liquid Biopsy Practice for EGFR Testing in Non-Small Cell Lung Cancer (NSCLC) Patients
por: Cortiula, Francesco, et al.
Publicado: (2020)

Longitudinal liquid biopsy anticipates hyperprogression and early death in advanced non-small cell lung cancer patients treated with immune checkpoint inhibitors
por: Zulato, Elisabetta, et al.
Publicado: (2022)

Detection of Loss of Heterozygosity in cfDNA of Advanced EGFR- or KRAS-Mutated Non-Small-Cell Lung Cancer Patients
por: Boldrin, Elisa, et al.
Publicado: (2019)

Mechanisms of resistance to osimertinib
por: Lazzari, Chiara, et al.
Publicado: (2020)

Early assessment of KRAS mutation in cfDNA correlates with risk of progression and death in advanced non-small-cell lung cancer
por: Zulato, Elisabetta, et al.
Publicado: (2020)

How the COVID-19 Pandemic Impacted on Integrated Care Pathways for Lung Cancer: The Parallel Experience of a COVID-Spared and a COVID-Dedicated Center
por: Pasello, Giulia, et al.
Publicado: (2021)

LKB1 and Tumor Metabolism: The Interplay of Immune and Angiogenic Microenvironment in Lung Cancer
por: Bonanno, Laura, et al.
Publicado: (2019)

Subacute Cutaneous Lupus Erythematosus-Like Eruption Induced by EGFR -Tyrosine Kinase Inhibitor in EGFR-Mutated Non-small Cell Lung Cancer: A Case Report
por: Ferro, Alessandra, et al.
Publicado: (2021)

Small bowel edema and lymphocytic duodenitis as severe reversible gastrointestinal toxicity of selpercatinib in RET fusion–positive non–small cell lung cancer: a case report
por: Scattolin, Daniela, et al.
Publicado: (2023)

Osimertinib in the treatment of non-small-cell lung cancer: design, development and place in therapy
por: Santarpia, Mariacarmela, et al.
Publicado: (2017)

Loss of nucleosome remodelers CHRAC/ACF does not sensitize early Drosophila embryos to X-rays
por: Scacchetti, Alessandro, et al.
Publicado: (2020)

Immunotherapy in small-cell lung cancer: from molecular promises to clinical challenges
por: Pavan, A., et al.
Publicado: (2019)

A Phase II Trial on Osimertinib as a First-Line Treatment for EGFR Mutation-Positive Advanced NSCLC in Elderly Patients: The SPIRAL-0 Study
por: Chihara, Yusuke, et al.
Publicado: (2022)

Osimertinib in Elderly Patients with Epidermal Growth Factor Receptor T790M‐Positive Non‐Small‐Cell Lung Cancer Who Progressed During Prior Treatment: A Phase II Trial
por: Nakao, Akira, et al.
Publicado: (2019)

Detection of Low-Frequency KRAS Mutations in cfDNA From EGFR-Mutated NSCLC Patients After First-Line EGFR Tyrosine Kinase Inhibitors
por: Nardo, Giorgia, et al.
Publicado: (2021)

Overview on Therapeutic Options in Uncommon EGFR Mutant Non-Small Cell Lung Cancer (NSCLC): New Lights for an Unmet Medical Need
por: Pretelli, Giulia, et al.
Publicado: (2023)

SRC and PIM1 as potential co-targets to overcome resistance in MET deregulated non-small cell lung cancer
por: Attili, Ilaria, et al.
Publicado: (2020)

A Phase II Trial of a Histone Deacetylase Inhibitor Panobinostat in Patients With Low-Grade Neuroendocrine Tumors
por: Jin, Ning, et al.
Publicado: (2016)

A Phase II Study of Everolimus Plus Oral Prednisone in Patients with Metastatic Renal Cell Cancer
por: Lolli, Cristian, et al.
Publicado: (2017)

Multicenter Real-World Study on Effectiveness and Early Discontinuation Predictors in Patients With Non-small Cell Lung Cancer Receiving Nivolumab
por: Pasello, Giulia, et al.
Publicado: (2022)

Radiological response and survival in locally advanced non-small-cell lung cancer patients treated with three-drug induction chemotherapy followed by radical local treatment
por: Bonanno, Laura, et al.
Publicado: (2016)

Prolonged Pemetrexed Infusion Plus Gemcitabine in Refractory Metastatic Colorectal Cancer: Preclinical Rationale and Phase II Study Results
por: Passardi, Alessandro, et al.
Publicado: (2017)

Acquired Resistance to Osimertinib in EGFR-Mutated Non-Small Cell Lung Cancer: How Do We Overcome It?
por: Bertoli, Elisa, et al.
Publicado: (2022)

Instruments for cataract surgery: results from our survey
por: Patel, Daksha, et al.
Publicado: (2011)

Certain types of iron oxide nanoparticles are not suited to passively target inflammatory cells that infiltrate the brain in response to stroke
por: Harms, Christoph, et al.
Publicado: (2013)

Sequencing analysis of the spinal bulbar muscular atrophy CAG expansion reveals absence of repeat interruptions()
por: Fratta, Pietro, et al.
Publicado: (2014)

Effects of Exercise on Progranulin Levels and Gliosis in Progranulin-Insufficient Mice1,2,3
por: Arrant, Andrew E., et al.
Publicado: (2015)

No Evidence for Sex Differences in the Electrophysiological Properties and Excitatory Synaptic Input onto Nucleus Accumbens Shell Medium Spiny Neurons123
por: Willett, Jaime A., et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_c20gkndg46feg6fhgi93fpm0ru